Close Menu

BG Medicine

NEW YORK (GenomeWeb News) – BG Medicine said today that the Nasdaq Listing Qualifications Panel has granted its request to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market.

Agilent Technologies said this week that Lars Holmkvist has resigned from his position as senior VP of the company and group president of its Life Sciences and Diagnostics Group.

NEW YORK (GenomeWeb News) – BG Medicine said today that the Centers for Medicare and Medicaid Services have published the final determination of the 2014 Medicare national limitation amount for the company's galectin-3 test, arriving at a price of $30.01.

NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet another requirement to remain listing on the Nasdaq Global Market, the company said in a document filed with the US Securities and Exchange Commission on Wednesday.

BG Medicine this week announced the publication of a multicenter clinical trial that found that the company's BGM Galectin-3 test was useful in predicting unplanned hospital readmissions and fatal events in heart failure patients.

NEW YORK (GenomeWeb News) – Nasdaq has notified BG Medicine that the company has not regained compliance with a listing requirement calling for at least $50 million in market value of its listed securities for continued listing on the exchange, BG Medicine said in a regulatory document.

Orbitrap inventor Alexander Makarov has been appointed professor of high resolution mass spectrometry at Utrecht University's Bijvoet Center.
Makarov is director of global researcher, life sciences mass spectrometry for Thermo Fisher Scientific.

BG Medicine this week reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.

NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.

NEW YORK (GenomeWeb News) – BG Medicine said after the close of the market Friday that it has been notified by Nasdaq for the third time in less than a year that it does not fulfill a requirement for continued listing on the exchange.

Pages

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.